Pioneering Early Detection For Neurodegenerative Diseases

Neurodegenerative disorders (NGDs) affect millions worldwide. We are committed to creating novel testing solutions for early detection to provide clinicians, researchers, and individuals with the tools to effectively diagnose, treat, and manage NGDs.

Our Pipeline

Resonant has a robust pipeline of NGD tests. Our test for early Alzheimer’s detection will be released for clinical use in Q1 of 2024.

Protect Your Mental Well-Being: Get Screened

Preserve your brain health. Understand your Neurodegenerative Disease status.
Join the Waitlist
Join the waitlist

Become the first to know when we open our tests to the public.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Join the waitlist

Become the first to know when we open our tests to the public.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Read About Our Peer Reviewed Alzheimer's Research

Recently published in Frontiers in Neurology, Resonant researchers validate a novel method of disease detection that overcomes limitations of specificity by analyzing cell-specific DNA methylation markers in the blood.
Learn More

Contact Us

Interested in applying this novel technology to your research, clinic(s), or early disease monitoring programs?

Contact Us Today

412 W River's Edge Dr.
Provo UT 84604

Contact Us
Copyright © 2023 Resonant. All rights reserved.
Join the waitlist

Become the first to know when we open our tests to the public.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.